{"entity":{"id":"nct03844048","kind":"trial","name":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","aka":[],"tldr":"A phase 3 trial of Venetoclax in multiple myeloma and non-hodgkin lymphoma, run by AbbVie, active and no longer recruiting.","summary":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial is a phase 3 interventional study registered as NCT03844048 by AbbVie, with 165 participants enrolled, started 2019-09-06 and due to reach its primary completion in 2027-08. Interventions recorded: Venetoclax. Conditions listed: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03844048","url":"https://clinicaltrials.gov/study/NCT03844048"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","non-hodgkin-lymphoma"],"sections":[],"technologies":["bcl2-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["venetoclax"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03844048","phase":"3","setting":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","sponsor":"AbbVie","participation":[{"nct":"NCT03844048","source":"https://clinicaltrials.gov/study/NCT03844048","fetchedAt":"2026-10-07T16:53:10.205Z","studySha256":"e07f92f29f7bf6e08db86398611fef9e2835cf8f299e0a068d393b9ecd3e85b0","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-05-13","leadSponsor":"AbbVie","collaboratorCount":0,"sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":165,"enrolmentType":"ACTUAL","siteCount":56,"recruitingSiteCount":0,"countries":["Australia","Austria","Belgium","Canada","Denmark","France","Greece","Hong Kong","Ireland","Japan","Mexico","New Zealand","Poland","Portugal","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom","United States"]}],"started":"2019-09-06","startedType":"actual","enrolled":165,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03844048/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}